Rockville-based Human Genome Sciences Inc., which last week rejected an unsolicited $2.6 billion acquisition offer by GlaxoSmithKline PLC, reported higher revenue and cut losses on sales of its new lupus drug.
Human Genome Sciences had first-quarter revenue of $47.1 million, compared with $26.6 million a year earlier. Benlysta sales accounted for $32.1 million in revenue. Sales of its anthrax treatment to the U.S. government stockpile contributed $6.1 million.